RSRafael Sanchez-Salas

Rafael Sanchez-Salas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rafael Sanchez-Salas has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    B2B: Prostate Cancer Summary

    by Caroline M. Moore, Alistair Grey, Kara Watts, Rafael Sanchez-Salas, Hashim Ahmed, Derya Tilki, Silvia Secco, John W. Davis, Alan McNeill, Nick James, et al.

    The 7th Bench-to-Bedside Uro-Oncology: GU Cancers Triad Meeting, organized in conjunction with the 45th Annual Congress of the Société Internationale d’Urologie, was held on 31 October 2025, in Edinburgh, Scotland, and transmitted live on the SIU@U Congress app

  • Lower urinary tract symptoms after robot-assisted radical prostatectomy: a systematic review

    by Felipe Santos Marimpietri, Rafael Tourinho-Barbosa, Rocío Roldan-Testillano, Lucas Teixeira Batista, Rafael Sanchez-Salas

    Robot-assisted radical prostatectomy (RARP) is a minimally invasive treatment for localized prostate cancer, offering potential advantages in urinary funct


  • Open Access

    Refined Procedure to Purify and Sequence Circulating Cell-Free DNA in Prostate Cancer

    by Samira Rahimirad, Seta Derderian, Lucie Hamel, Eleonora Scarlata, Ginette McKercher, Fadi Brimo, Raghu Rajan, Alexis Rompre-Brodeur, Wassim Kassouf, Rafael Sanchez-Salas, et al.

    Cell-free DNA (cfDNA), a fragmented DNA circulating in blood, is a promising biomarker for cancer diagnosis and monitoring. Standardization of cfDNA isolation to enhance the sensitivity of molecular analyses in prostate cancer (PCa) is required. Towards this goal, we optimized existing methods to obtain a high quantity and quality of cfDNA from low volumes of plasma. The protocol was applied to samples from healthy males and three patient categories: radical prostatectomy (RP), disease-free (>6 years post-RP), and metastatic castration-resistant PCa (mCRPC). The yield was significantly higher in mCRPC cases, and the size of fragments was shorter. We compared for the first time library preparation using two cfDNA inputs and low vs. high sequencing depth. Clonal events were observed irrespective of input and depth, but lower input showed more subclonal events. The clinical application of the refined protocols to cfDNA samples from an mCRPC patient showed no tumor fraction before RP, while it increased to 25% at the advanced stage. Among chromosomal changes and mutations, the androgen receptor gene amplification was detected. Altogether, this comprehensive study on improved cfDNA procedures is highly promising to enhance the quality of liquid biopsy-based research for discoveries and much-needed clinical applications.


  • Open Access

    SIU-ICUD: Focal Therapy for PCa — The Technique

    by Lara Rodriguez-Sanchez, Thomas J. Polascik, Kara Watts, Peter Ka-Fung Chiu, Mark Emberton, Behfar Ehdaie, Hashim U. Ahmed, Andre Abreu, Ardeshir R. Rastinehad, Rafael Sanchez-Salas

    Background/Objectives: Focal therapy (FT) and technology are closely connected. Advanced imaging allows for precise identification of the index lesion, enabling the targeted use of various thermal and non-thermal energy sources through different approaches, with specific techniques tailored to lesion location and operator expertise. This personalized approach enhances both safety and effectiveness, facilitating customized treatment planning. Methods: The International Consultation on Urological Diseases formed a committee to review the current literature on FT for prostate cancer (PCa), focusing specifically on the technique. Following in-depth discussions, the committee chose a “by lesion” approach rather than the traditional “by energy” approach to structure the review. A comprehensive PubMed search was conducted to gather relevant articles on the various energy modalities and procedural approaches used in FT for PCa. Results: Lesions in the apex, anterior, and posterior regions of the prostate can be accessed through several FT approaches, each associated with specific energy modalities and techniques. The transrectal approach utilizes high-intensity focused ultrasound (HIFU) and focal laser ablation (FLA), while the transperineal approach is compatible with energy sources such as cryotherapy, irreversible electroporation (IRE), brachytherapy, and FLA. The transurethral approach supports methods such as transurethral ultrasound ablation (TULSA). Each approach offers distinct advantages based on lesion location, treatment area, and energy modality. The choice of technique evaluated the safety and efficacy of each energy source and approach based on specific treatment areas within the prostate, highlighting the need for robust research across lesion locations and modalities, rather than focusing solely on each modality for a specific region. Conclusions: FT is rapidly advancing with new energy sources, technological improvements, and increasing operator expertise. To further optimize FT, research should prioritize evaluating the safety and effectiveness of different energy sources for various lesion locations, focusing on the treatment area rather than the energy modality itself.


  • Urinary Symptoms Change and Quality of Life After Robotic Radical Prostatectomy: A Secondary Analysis of a Randomized Controlled Trial

    by Rafael Tourinho-Barbosa, Rafael Sanchez-Salas, Arjun Sivaraman, Rafael Castilho Borges, Luigi Candela, Lucas Teixeira Batista, Nathalie Cathala, Annick Mombet, Giancarlo Marra, Lara Rodriguez Sanchez, et al.


  • The diagnostic accuracy of micro-ultrasound for prostate cancer diagnosis: a review

    by Pier Paolo Avolio, Giovanni Lughezzani, Maurice Anidjar, Toufic Hassan, Alexis Rompré-Brodeur, Nicolò Maria Buffi, Massimo Lazzeri, Rafael Sanchez-Salas

    Purpose Micro-UltraSound (microUS) is a new imaging modality capable of identifying and targeting suspicious areas, which might further increase the diagnostic yield of prostate biopsy (PBx). Aim of this review is to provide insights into the usefulness of microUS for the sub-stratification of prostate cancer (PCa), clinically significant PCa (i.e., any Gleason score ≥ 7 PCa; csPCa) along with non-organ-confined disease in patients undergoing PBx. Methods A PubMed literature search was performed using keywords: prostate cancer diagnosis, prostate cancer diagnosis surveillance, systematic biopsy, target biopsy, micro-ultrasound, and prostate risk identification using micro-ultrasound. Results MicroUS could significantly improve multiparametric magnetic resonance imaging (mpMRI) findings by adding valuable anatomical and pathological information provided by real-time examination. Furthermore, microUS target biopsy could replace systematic biopsy in clinical practice by reducing the detection of clinically insignificant (ciPCa) and increasing that of csPCa. Finally, microUS may be useful in predicting the presence of non-organ confined PCa before radical prostatectomy and it could also be an effective add-on tool for patient monitoring within the active surveillance program. Conclusion MicroUS may represent an attractive step forward for the management of csPCa as a complementary or alternative tool to mpMRI. Nevertheless, further longitudinal studies are warranted, and the strength of the evidence is still suboptimal to provide clear recommendations for daily clinical practice.